Figure 6.

Therapeutic administration of sclerostin antibody to arthritic mice reverses systemic bone loss. (A) Bar plot represents mean (and standard deviation of) bone mineral density (BMD) assessed by dual X-ray absorptiometry (DEXA) in vehicle (collagen-induced arthritis (CIA) + PBS; n = 14) or sclerostin antibody (Scl-AbI) (CIA + Scl-AbI; n = 11) treated mice. An additional group of untreated diseased mice (n = 7) were scanned 14 days after onset of arthritis. These mice were used to represent baseline BMD at initiation of therapeutic dosing. BMD in age-matched healthy control mice (CTR; n = 4) was also assessed. (B, C) Bar plots represent mean (and standard deviation of) trabecular bone volume fraction (BV/TV) in the L5 vertebral body and trabecular thickness (Tb.Th). (D, E) Bar plots represent mean (and standard deviation of) trabecular bone volume fraction (BV/TV) the tibial metaphysis and cortical thickness of the cortical bone in the tibia midshaft. The one-way ANOVA test with Tukey's post hoc comparison was used for statistical evaluation of all parameters shown in the bar plots. *P < 0.05 for the difference versus control (CTR); #P < 0.05 for the difference versus CIA + PBS.

Marenzana et al. Arthritis Research & Therapy 2013 15:R125   doi:10.1186/ar4305
Download authors' original image